MR analysis using the cis‐SNP found that IGF‐I was significantly associated with a 34% increased prostate cancer risk per 5 nmol/L increment (95% CI 1.07‐1.68; P = .01) (Table 2; Supplementary Figure S3). Here, IGF1 is linked to prostate carcinoma.